Data on the relationship between ribosome biogenesis and p53 function indicate that the tumour suppressor can be activated by either nucleolar disruption or ribosomal protein defects. However, there is increasing evidence that the induction of p53 does not always require these severe cellular changes, and data are still lacking on a possible role of ribosome biogenesis in the downregulation of p53. Here, we studied the effect of the up-and downregulation of the rRNA transcription rate on p53 induction in mammalian cells. We found that a downregulation of rRNA synthesis, induced by silencing the POLR1A gene coding for the RNA polymerase I catalytic subunit, stabilised p53 without altering the nucleolar integrity in human cancer cells. p53 stabilisation was due to the inactivation of the MDM2-mediated p53 degradation by the binding of ribosomal proteins no longer used for ribosome building. p53 stabilisation did not occur when rRNA synthesis downregulation was associated with a contemporary reduction of protein synthesis. Furthermore, we demonstrated that in three different experimental models characterised by an upregulation of rRNA synthesis, cancer cells treated with insulin or exposed to the insulin-like growth factor 1, rat liver stimulated by cortisol and regenerating rat liver after partial hepatectomy, the p53 protein level was reduced due to a lowered ribosomal protein availability for MDM2 binding. It is worth noting that the upregulation of rRNA synthesis was responsible for a decreased p53-mediated response to cytotoxic stresses. These findings demonstrated that the balance between rRNA and ribosomal protein synthesis controls the function of p53 in mammalian cells, that p53 can be induced without the occurrence of severe changes of the cellular components controlling ribosome biogenesis, and that conditions characterised by an upregulated rRNA synthesis are associated with a reduced p53 response.
Data on the relationship between ribosome biogenesis and p53 function indicate that the tumour suppressor can be activated by either nucleolar disruption or ribosomal protein defects. However, there is increasing evidence that the induction of p53 does not always require these severe cellular changes, and data are still lacking on a possible role of ribosome biogenesis in the downregulation of p53. Here, we studied the effect of the up-and downregulation of the rRNA transcription rate on p53 induction in mammalian cells. We found that a downregulation of rRNA synthesis, induced by silencing the POLR1A gene coding for the RNA polymerase I catalytic subunit, stabilised p53 without altering the nucleolar integrity in human cancer cells. p53 stabilisation was due to the inactivation of the MDM2-mediated p53 degradation by the binding of ribosomal proteins no longer used for ribosome building. p53 stabilisation did not occur when rRNA synthesis downregulation was associated with a contemporary reduction of protein synthesis. Furthermore, we demonstrated that in three different experimental models characterised by an upregulation of rRNA synthesis, cancer cells treated with insulin or exposed to the insulin-like growth factor 1, rat liver stimulated by cortisol and regenerating rat liver after partial hepatectomy, the p53 protein level was reduced due to a lowered ribosomal protein availability for MDM2 binding. It is worth noting that the upregulation of rRNA synthesis was responsible for a decreased p53-mediated response to cytotoxic stresses. These findings demonstrated that the balance between rRNA and ribosomal protein synthesis controls the function of p53 in mammalian cells, that p53 can be induced without the occurrence of severe changes of the cellular components controlling ribosome biogenesis, and that conditions characterised by an upregulated rRNA synthesis are associated with a reduced p53 response.
Introduction
The tumour suppressor p53 is a transcription factor that is activated by a variety of cellular stresses. p53 activates the transcription of genes involved in cell-cycle arrest, DNA repair, senescence, inhibition of angiogenesis and apoptosis, thus greatly contributing to hindering tumourigenesis (Vogelstein et al., 2000; Lowe et al., 2004; Vousden and Lane, 2007) . As for the mechanism of p53 activation, available data indicate that the latter is mainly the consequence of changes in functional and physical interactions of the tumour suppressor with MDM2. MDM2 adversely controls p53 activity in two ways: by binding to the protein and interfering with its transactivation activity, and by facilitating p53 proteasomal degradation, acting as an E3 ubiquitin ligase (Momand et al., 1992; Haupt et al., 1997; Kubbutat et al., 1997) .
Recently, the disruption of ribosome biogenesis has been shown to cause p53 stabilisation, as a consequence of the release from the nucleolus of several ribosomal proteins that bind to MDM2 and relieve its inhibitory activity toward p53 (see the reviews by Zhang and Lu, 2009; Deisenroth and Zhang, 2010) . In fact, the large subunit ribosome proteins rpL5, rpL11 and rpL23 were all reported to bind MDM2, thus inducing p53 stabilisation by inhibiting its E3 ubiquitin ligase function (Lohrum et al., 2003; Zhang et al., 2003; Bhat et al., 2004; Jin et al., 2004) . The impairment of the nucleolar function has been proposed as a common denominator of many signalling pathways leading both to the suppression of MDM2 function and to p53 stabilisation and activation (Rubbi and Milner, 2003) . According to this model, a stress must always acutely damage a fundamental cellular function to induce p53 activation. This might be functionally conceivable if the p53 activity were restricted to the stop in cell cycle progression and/or to the induction of apoptotic programmed death in injured proliferating cells, in order to avoid the transmission of the damage to daughter cells. However, it is hard to suppose that a similar cell-injuring mechanism would be required to modulate the so-called 'everyday p53 functions' (Vousden and Prives, 2009 ) that control a series of metabolic pathways other than the tumour suppressive response to acute stress. Therefore, we wondered whether a specific downregulation of rRNA synthesis must necessarily disrupt the nucleolus and induce ribosomal protein leakage to stabilise and activate p53. We demonstrated that a downregulation of rRNA synthesis induced by silencing the POLR1A gene coding for the RNA polymerase I catalytic subunit stabilised p53 without giving rise either to structural changes in the nucleolar components or leakage of the nucleolar proteins to the nucleoplasm. As we found that, according to the available evidence (see reviews by Zhang and Lu, 2009; Deisenroth and Zhang, 2010) , the inhibition of the synthesis of rRNA was associated with an increased binding of rpL5 and rpL11 to MDM2, we investigated whether p53 stabilisation also occurred in experimental models in which the synthesis of rRNA and ribosomal proteins was reduced at the same time, such as in cells after serum deprivation or exposure to rapamycin (O'Mahony et al., 1992; Mahajan, 1994; Glibetic et al., 1995; Hannan et al., 2003; Caldarola et al., 2004; Gera et al., 2004; Bilanges et al., 2007) . The data obtained, showing no p53 stabilisation in either conditions, indicated that p53 was stabilised only when the reduction of rRNA synthesis was not accompanied by a similar variation in the synthesis of ribosomal proteins, that is, when a relative increase in ribosomal protein availability for MDM2 binding was induced. These results prompted us to further elucidate the relationship between p53 stabilisation and the balance of rRNA and ribosomal protein synthesis, while investigating the possibility that rRNA synthesis upregulation might reduce p53 stabilisation through an increased use of ribosomal proteins for ribosome building and, therefore, a reduced availability of ribosomal proteins for MDM2 binding. Indeed, we found that in three different experimental models characterised by a stimulation of ribosomal biogenesis, (cancer cells treated with insulin or exposed to the insulin-like growth factor 1 (IGF-1), rat liver stimulated by cortisol and regenerating rat liver after partial hepatectomy), the p53 protein level and activity were reduced as a consequence of an increased p53 proteasomal degradation due to a lower binding of ribosomal proteins to MDM2.
Results

POLR1A silencing stabilises p53 without disrupting the nucleolar structure
In a preliminary study, we demonstrated that in human cancer cell lines, the silencing of the POLR1A gene by the siRNA procedure inhibited the expression of POLR1A mRNA and gave rise to a selective inhibition of rRNA synthesis (Donati et al., submitted) . Here, we confirmed that POLR1A silencing caused a progressive reduction in the synthesis of rRNA in U2OS human cancer cells, and we showed that the downregulation of rRNA synthesis induced by POLR1A silencing stabilised p53 without causing any change in the nucleolar structural organisation and the release of the nucleolar proteins. We found that p53 was accumulated as early as 24 h after the end of the POLR1A silencing procedure and its amount was increased in 48 h-silenced cells, as revealed by western blot analysis (Figure 1a) . The p53 accumulation level paralleled the reduction of rRNA synthesis as measured by reverse transcriptase-PCR (RT-PCR) evaluation of the 45S rRNA ( Figure 1b) and 5-fluorouridine nucleolar incorporation (Figure 1c) . At 48 h after POLR1A silencing, electron microscopy ( Figure 1d) showed that, in comparison with U2OS cells transfected with control sequences, the nucleoli of POLR1A-silenced cells appeared to be smaller in size with a reduced amount of fibrillar components (fibrillar centres plus the associated dense fibrillar component), which represent the structural-functional units of the nucleolus (Montanaro et al., 2008) . However, the ribonucleoprotein components did not exhibit any change, such as segregation or fragmentation (shown in Supplementary Figure S1 ), of their distribution within the nucleolar body, which are indicative of disrupted nucleolar structure. As nucleophosmin translocation from the nucleolus to the nucleoplasm is considered to represent a marker of nucleolar changes (Chan et al., 1996) , we analysed the distribution of nucleophosmin in 48 h-POLR1A-silenced cells. We found that after POLR1A silencing, only a reduction of the immunocytochemical labelling of nucleophosmin was observed in nucleoli without any diffusion of the protein to the nucleoplasmic compartment (Figure 1e ). Lastly, we wondered whether POLR1A silencing induced changes in the location of ribonucleoproteins to the nucleolus. As we failed to obtain an interpretable immunofluorescent staining using antibodies versus either rpL5 or rpL11, we analysed the distribution of the rpS14, a ribosomal protein incorporated early in ribosome formation (Kruger et al., 2007) . At 48 h after the end of POLR1A silencing procedure, no translocation of rpS14 from the nucleolus to the nucleoplasm was detected in U2OS cells (Figure 1f ). All together, these data led us to conclude that the inhibition of rRNA synthesis by POLR1A silencing induced p53 stabilisation without any evidence of nucleolar disruption and nucleolar protein leakage.
In order to extend our analysis to the relationship among rRNA synthesis inhibition, nucleolar disruption and p53 stabilisation, we also evaluated the effect of 5-fluorouracyl exposure on p53 expression and nucleolar structural organisation in U2OS cells. The reduction of rRNA synthesis induced by the drug was associated with p53 stabilisation without alteration, once again, in the nucleolar ultrastructural morphology and nucleophosmin translocation to the nucleoplasm (Supplementary Figure S2) . p53 stabilisation after POLR1A silencing is due to MDM2 inactivation by ribosomal proteins p53 levels are regulated by the oncoprotein MDM2 that mediates the tumour suppressor ubiquitylation and proteasome-dependant degradation (Momand et al., 1992; Haupt et al., 1997; Kubbutat et al., 1997) . Several ribosomal proteins have been shown to inhibit this MDM2 function after the perturbation of ribosome biogenesis, thus leading to p53 stabilisation and activation (Zhang and Lu, 2009 ); therefore, we wondered whether this mechanism of p53 level regulation was active also after inhibition of rRNA synthesis by POLR1A silencing. First, we evaluated the half-life of p53 by time-course western blot analysis in control and POLR1A-silenced U2OS cells after treatment with Cycloheximide at a dose capable of completely inhibiting protein synthesis. We found that the half-life of p53 in POLR1A-silenced cells was longer than that of control cells (Figure 2a) . Therefore, we considered the possibility that the higher p53 level after the inhibition of (e) Visualisation of nucleophosmin (NPM) distribution in control and POLR1A-silenced U2OS cells, 48 h after the end of the silencing procedure. Cells were labelled with monoclonal antibodies versus nucleophosmin; the antibodies were revealed by FITCH-conjugated secondary antibodies. Nuclei were stained with DAPI (DAPI). U2OS cells transfected with control sequences (Ctrl) exhibit the nucleolar localisation of NPM. In U2OS cells silenced for POLR1A expression and stained with DAPI, the nucleolar bodies are identifiable by the reinforced DAPI-staining of perinucleolar chromatin (DAPI); after NPM immunostaining, the FITCH-related signals appear to have the same distribution as the nucleolar bodies (NPM), as also revealed by the merged DAPI and FITCH images (Merge). Scale bar, 10 mm. (f) Visualisation of rp S14 distribution in control and POLR1A-silenced U2OS cells, 48 h after the end of the silencing procedure. Cells were labelled with anti-ribosomal protein S14 antibodies; the antibodies were revealed by FITCH-conjugated secondary antibodies. DAPI nuclear staining. Scale bar, 10 mm. Histograms show the values (mean±s.d.) of three experiments.
rRNA transcription modulates p53 G Donati et al rRNA synthesis might be due to its reduced degradation via the ubiquitin-proteasome pathway. Indeed, we showed that the following was the case: after blocking the proteasome activity with the small inhibitor molecule MG-132, we observed that the level of p53 in POLR1A-silenced cells for the time intervals considered did not change, whereas it progressively increased in control cells, as evaluated by western blot analysis ( Figure 2b ). To obtain a mechanistic insight into how POLR1A silencing increased the level of p53, we evaluated whether POLR1A silencing caused quantitative changes in the ribosomal protein mRNA translational activity. As we found that the level of the rpL5 and rpL11 mRNAs associated with polyribosomal fractions was similar both in control and in 48 h-POLR1A-silenced cells, as evaluated by real-time RT-PCR ( Figure 2c ), we concluded that POLR1A interference did not induce variations in rpL5 and rpL11 synthesis. At this point, we looked for quantitative changes in the binding of rpL5 and rpL11 to MDM2 by co-immunoprecipitation analysis. We observed that the amount of both proteins co-immunoprecipitated with MDM2 increased in POLR1A-silenced cells in comparison with control cells (Figure 2d ). The importance of the ribosomal proteins in determining p53 stabilisation after POLR1A silencing was stressed by the observation that RPL11 silencing hindered accumulation of p53. Double RPL11 and POLR1A interference strongly reduced the expression of the relative mRNAs ( Figure 2d ). Western blot analysis of p53 expression showed that POLR1A interference did not stabilise the protein in rpL11-silenced cells (Figure 2f ), thus demonstrating that rpL11 availability was necessary for p53 stabilisation in POLR1A-silenced cells. In order to rule out that p53 stabilisation in POLR1A-silenced cells might be due to the inactivation of MDM2 consequent to its nucleolar sequestration, as described in other experimental models (Bates et al., 1998; Lohrum et al., 2003; Bernardi et al., 2004) , we also evaluated the distribution of MDM2 in control and POLR1A-silenced U2OS cells by immunocytochemistry. We found that POLR1A silencing did not induce any accumulation of MDM2 in nucleoli (Supplementary Figure S3) . Therefore, all together, these data were consistent with a ribosomal-protein-mediated mechanism of p53 stabilisation after rRNA synthesis downregulation, even though the possibility that p53 stabilisation might be at least partially mediated by a MDM2/ubiquitination-independent mechanism could not be ruled out. In fact, there is evidence that 20S proteasomes degrade p53 and the degradation does not require ubiquitination of p53 (Gong et al., 2007) . Interestingly, this mechanism is hindered by the cytosolic quinone oxidoreductases NQO1 and NQO2, which interact with p53 and protect p53 against 20S proteasomal degradation. Acute cell stresses, such as radiation or chemical exposure and pyrimidine nucleotides deficiency lead to induction of NQO1 and NQO2 that stabilizes and transiently activates p53 and downstream genes (Khutornenko et al., 2010) .
The contemporary downregulation of rRNA and ribosome protein synthesis does not stabilise p53
The above reported data strongly suggest that the imbalance between rRNA and ribosomal protein synthesis was responsible for p53 stabilisation after POLR1A silencing as a consequence of an increased availability of ribosome-free ribosomal proteins that bind and inhibit MDM2. To further demonstrate the importance of rRNA and ribosomal protein synthesis balance in modulating p53 expression, we investigated whether p53 stabilisation occurred in experimental conditions characterised by a reduction in both rRNA and ribosomal protein synthesis. For this purpose, we used either the serum starvation procedure or the rapamycin treatment. After 24 h of serum starvation, the amount of 45S rRNA as detected by RT-PCR analysis was reduced in U2OS cells as well as 5-fluorouridine incorporation into nucleolar rRNA, as detected by immunofluorescence evaluation (Figure 3a) . Also reduced was p53 expression, as evaluated by western blot analysis (Figure 3b ). At that time, the translation level of the rpL5 and rpL11 mRNAs was also markedly reduced (Figure 3c ), as well as the nuclear amount of these proteins (Figure 3d ). Analysis of polysomal profiles of both starved and rapamycintreated cells (Figures 3c and g ) indicated that the global rRNA transcription modulates p53 G Donati et al level of protein synthesis also was reduced in these conditions, in comparison with control cells. These data were consistent with the absence of p53 stabilisation after serum deprivation observed in TGR-1 cells (Ho¨lzel et al., 2005) , but not with the reported activation of p53 in WI-38 cells after serum starvation (Bhat et al., 2004) , thus suggesting that serum starvation may induce a cell-specific p53 activation.
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Regarding the experiments with rapamycin, MCF-7 cells were used because of the very low sensitivity of the U2OS cells to the drug exposure. Treatment with 20 nM rapamycin for 24 h strongly reduced both the amount of 45S rRNA as detected by RT-PCR analysis and the nucleolar 5-fluorouridine immunofluorescent staining (Figure 3e) . In rapamycin-treated cells, the expression of p53 appeared to be reduced (Figure 3f) . Rapamycin treatment induced a reduction in the translation of the rpL5 and rpL11 mRNAs (Figure 3g) . Therefore, these results indicated that serum starvation and rapamycin treatment, both conducted for a time period of 24 h, were responsible for a downregulation of both rRNA and ribosomal protein synthesis. In these conditions, we found that the level of p53 expression not only was not increased but, in fact, was reduced, likely as a consequence of the reduced p53 mRNA translation. In order to further clarify the mechanism of p53 stabilisation after POLR1A silencing, we evaluated the effect of serum starvation on POLR1A-silenced U2OS cells. We found that serum starvation prevented p53 accumulation also in POLR1A-silenced cells, thus indicating that p53 accumulation after the inhibition of rRNA synthesis by POLR1A interference was strictly dependant upon availability of newly synthesised ribosomal proteins (Figure 3h ).
It might be suggested that the reduced rRNA synthesis did not induce p53 accumulation in serumstarved cells only because p53 accumulation was prevented as a consequence of the protein synthesis reduction. To clarify this point, we treated serumstarved and rapamycin-treated cells with a drug, the actinomycin D, that, at the dose used, selectively inhibits rRNA transcription (Montanaro et al., 2007) and disrupts the nucleolar structure causing ribosomal protein leakage from the nucleolus to the nucleoplasm (Rubbi and Milner, 2003) . Exposure to actinomycin D completely inhibited rRNA transcription in starved and rapamycin-treated cells, as evaluated by RT-PCR analysis of the 45S rRNA and by nucleolar 5-fluorouridine immunofluorescent staining (Supplementary Figure S4 ). We found that, in the actinomycin D-exposed cells, p53 accumulation occurred again (Figure 3i) , very likely as a consequence of MDM2 inactivation caused by the released nucleolar ribosomal proteins, thus indicating that p53 was sufficiently produced in starved and rapamycin-treated cells to be still stabilised upon stress.
Therefore, all together, these results led us to conclude that p53 stabilisation after the reduction of rRNA synthesis by POLR1A interference was actually due to a relatively increased availability of ribosomal proteins for MDM2 binding as a consequence of their reduced use in ribosome building.
rRNA synthesis upregulation increases p53 proteasomal degradation Then, we wondered whether in experimental conditions in which an upregulation of rRNA synthesis was induced, a reduction in ribosomal protein availability consequent to their use in ribosome building might occur, which could lead to both reduced inactivation of MDM2 and the consequently increased p53 proteasome degradation. To analyse the effect of a stimulation of rRNA synthesis on p53 stabilisation, we used three different experimental conditions: (1) cancer cell lines exposed either to insulin or to the IGF-1, (2) regenerating rat liver after partial hepatectomy, and (3) rat liver after intraperitoneal cortisol injection. Insulin and IGF-1 stimulate the activity of polymerase I transcription by elevating both UBF protein level and phosphorylation (Hannan et al., 1998; Wu et al., 2005) . Partial hepatectomy induces a progressive increase in rRNA synthesis (up to 24 h after operation) in regenerating rat hepatocytes (Sirri et al., 1995) very likely due to the induction of c-myc (Thompson et al., 1986) , which controls the RNA polymerase I activity (Arabi et al., 2005; Grandori et al., 2005; Grewal et al., 2005) . Cortisol at the dose used in the present experiments stimulated rRNA transcription in rat hepatocytes (Sirri et al., 1995) by activating the glycocorticoid receptor signalling (Glibetic et al., 1993) , while inhibiting their proliferation (Nadal, 1995) . The evaluation of rRNA transcription by real-time RT-PCR analysis of 45S rRNA indicated that rRNA synthesis was significantly increased in MCF-7 cells exposed to IGF-1, in H4-II-E-C3 cells treated with insulin, in regenerating rat livers 12 h after partial hepatectomy and in cortisol-stimulated rat livers 8 h after intraperitoneal hormone injection (Figure 4a ). In all these experimental conditions, we found that the expression of p53, as measured by western blot analysis, was reduced in cells in which rRNA synthesis was stimulated in comparison with the relevant controls ( Figure 4b) . As in the above-reported experimental conditions a series of signalling pathways are activated that might led to p53 downregulation independent of rRNA synthesis stimulation, we evaluated the effect of IGF-1 stimulation on p53 expression in MCF-7 cells after 48 h POLR1A silencing. We found that the synthesis of rRNA was downregulated both in control and IGF-1-treated cells silenced for POLR1A expression, as evaluated by real-time RT-PCR analysis of 45S rRNA. IGF-1 exposure did not modify the level of p53 expression in POLR1A-silenced cells, thus indicating the key role of rRNA synthesis upregulation in determining the reduction of p53 expression after IGF-1 stimulation (Figure 4c) .
In order to investigate the mechanism involved in the reduction of the p53 level after stimulation of rRNA synthesis, we first analysed the expression of the p53 mRNA in the MCF-7 cells exposed to IGF-1, the H4-II-E-C3 cells treated with insulin, the regenerating rat liver, and the rat liver after cortisol treatment. The evaluation of the p53 mRNA expression by real-time RT-PCR analysis indicated that, in all the experimental conditions of rRNA synthesis stimulation, no quantitative changes in TP53 transcription occurred (Figure 5a) . Therefore, we considered the possibility that the reduced level of p53 might be due to its increased proteasomal degradation. For this reason, we treated both IGF-1-stimulated MCF-7 cells and insulin-exposed H4-II-E-C3 cells with the proteasome inhibitor MG-132. We found that, in both experimental conditions, rRNA transcription modulates p53 G Donati et al the inhibition of proteasomal degradation cancelled the difference between the p53 expression of control and stimulated cells, as evaluated by western blot analysis (Figure 5b ), thus indicating that the changes in p53 level were actually due to an increased protein degradation. On the basis of the established mechanism of MDM2 control of p53 degradation, we wondered whether in the case of stimulation of rRNA synthesis a reduction of ribosomal protein binding to the MDM2 might occur, thus increasing the MDM2 degradation of p53. Therefore, we evaluated the quantitative changes of rpL5 and rpL11 bound to MDM2 by co-immunoprecipitation analysis: we found that the amount of the two ribosomal proteins co-immunoprecipitated with MDM2 was reduced in IGF-1-stimulated MCF-7 cells in comparison with control cells (Figure 5c ). In order to define the role of MDM2 in the reduction of p53 stabilisation after stimulation of rRNA synthesis, Figure 4 rRNA synthesis upregulation reduces p53 accumulation. (a) Real-time RT-PCR analysis of the 45S rRNA expression in control and MCF-7 cells exposed to IGF-1 at a dose of 100 ng/ml for 12 h; in control and in H4IIEC3 cells stimulated by insulin at 40 nM concentration for 16 h; and in control rat liver, in regenerating rat liver 12 h after partial hepatectomy and in rat liver 8 h after cortisol intraperitoneal injection at the dose of 10 mg/100 g body weight. (b) Representative western blot and densitometric analysis of p53 expression in control and MCF-7 cells exposed to IGF-1 at a dose of 100 ng/ml for 12 h, in control and in H4IIEC3 cells stimulated by insulin at 40 nM concentration for 16 h, in control and regenerating rat liver 12 h after partial hepatectomy and in control and 8 h cortisol-stimulated rat liver. rRNA transcription modulates p53 G Donati et al we evaluated the effect of the MDM2 inhibitor Nutlin-3 on p53 expression in control and IGF-1-stimulated MCF-7 cells. Nutlin-3 binds MDM2 in the p53-binding pocket, thus hindering the MDM2-mediated degradation of p53, which results in p53 stabilisation and activation (Vassilev et al., 2004) . Therefore, in the presence of a mechanism of p53 downregulation induced by enhancement of rRNA synthesis that was not mediated by an increased binding of MDM2 to p53, Nutlin-3 treatment should still result in a lower p53 expression after IGF-1 stimulation, in comparison with unstimulated cells. Western blot analysis of p53 expression in control and IGF-1-stimulated MCF-7 cells after Nutlin-3 exposure indicated that this was not the case. In fact, we found that Nutlin-3 induced a p53 stabilisation and activation that was quite similar in control and IGF-1 stimulated cells (Figure 5d ), thus strongly suggesting that the reduction of p53 expression after stimulation of rRNA synthesis was actually the consequence of an increased binding of MDM2 to p53.
rRNA synthesis upregulation reduces the expression of p53 target genes, also after drug-induced stress The observation that the level of p53 was reduced in cells in which the rRNA synthesis was stimulated prompted us to investigate whether the activity of p53 was also reduced in these cells. Therefore, we measured the expression of three p53-target genes whose products have a tumour suppressor function: p21, BAX and PUMA (Burns and El-Deiry, 1999; Sax and El-Deiry, 2003) . The quantitative analysis of the mRNA expression of these three genes by real-time RT-PCR indicated that BAX and PUMA mRNAs were significantly reduced in all the experimental conditions of upregulated rRNA synthesis. Regarding p21 mRNA expres- rRNA transcription modulates p53 G Donati et al sion, it appeared to be also reduced after rRNA synthesis stimulation, but with the exception of regenerating rat liver in which it was highly increased in comparison with control, resting liver (Figure 6a ). The latter observation is consistent with previous data showing that in regenerating hepatocytes after partial hepatectomy, the p21 mRNA was upregulated with enhanced expression during G1 phase (Albrecht et al., 1997) , and, in fact, we used regenerating rat livers that are in G1 phase, 12 h after partial hepatectomy, whereas the synthesis of DNA began only 15 h after surgery (Sirri et al., 1995) . At this point, we wondered whether the reduced p53 level in cells with increased rRNA synthesis might also be reflected in a reduced p53 stabilisation and activity after cytotoxic stress. For this purpose, we used IGF-1-stimulated MCF-7 cells treated with either hydroxyurea or gemcitabine. These drugs were chosen because they do not directly inhibit ribosome biogenesis (Derenzini et al., 1981; Burger et al., 2010 for hydroxyurea; Supplementary Figure S5 , for gemcitabine). Western blot analysis indicated that IGF-1 stimulation caused a reduction of p53 expression in MCF-7 cells treated with both drugs in comparison with unstimulated, drug-treated cells, and that amount of p53 was even lesser in cells treated with hydroxyurea and stimulated by IGF-1 than in control cells (Figure 6b ). Regarding the expression of the p53-target genes, we observed that the p21, BAX and PUMA mRNA level was markedly lower in IGF-1-stimulated than unstimulated MCF-7 cells after either hydroxyurea or gemcitabine treatment (Figure 6c ). Therefore, these results indicated that the upregulation of rRNA synthesis induced a lowering of the p53 level, which was responsible for the downregulation of the p53-target gene response after exposure to cytoxic stresses.
Discussion
This study demonstrated that the control of p53 stabilisation and activity in mammalian cells may be due to the balance between the rRNA and ribosomal proteins' synthesis. This mechanism of p53 stabilisation is schematically represented in Figure 7 . After selective downregulation of rRNA synthesis, the unchanged level of ribosomal protein translation allowed ribosomal proteins, which are no longer used for ribosome biogenesis, to bind in larger amounts to MDM2, thus increasing p53 stabilisation, likely as a consequence of the reduced MDM2-mediated p53 proteasomal degradation. Conversely, after upregulation of ribosomal biogenesis, the level of p53 stabilisation was lowered; this decrease was as a consequence of the increased MDM2-mediated p53 proteasomal degradation due to the reduced availability of ribosomal proteins for MDM2 binding, which were in fact used in a greater amount for ribosome building. When both the synthesis of rRNA and ribosomal proteins decreased, such as after either serum deprivation or rapamycin exposure, p53 was not stabilised.
A series of previous data led to the hypothesis that, in order to stabilise p53, all the cell stresses should induce a severe perturbation in the nucleolar structure with the release of the nucleolar proteins from the nucleolus to the nucleoplasm, the so-called 'nucleolar disruption' (Rubbi and Milner, 2003) . Our results demonstrated that these severe structural-functional changes of the nucleolus were not a necessary condition for p53 stabilisation. In fact, a downregulation of the synthesis of rRNA may cause p53 stabilisation without inducing the 'nucleolar disruption'.
In this way, mild environmental stresses, such as that induced by reduced nutrient availability, insulin/IGF signalling and hypoxia, can activate p53 for carrying out its 'every day functions', in order to settle the energy homoeostasis pathways of the cell according to the new metabolic necessities, without suffering structural and functional changes that may lead to cell death. Indeed, there is evidence for a role of p53 in modulating glucose uptake, reducing glycolysis and enhancing mitochondrial respiration (Bensaad and Vousden, 2007; Vousden and Ryan, 2009 ) that should be fulfilled without adding further severe damages to the cell. This mechanism of p53 activation may be also important for the modulation of those p53 functions that depend on basal levels of p53 or the activation of p53 by low levels of constitutive stress, such as the control of stem cell renewal (Meletis et al., 2006; Liu et al., 2009) .
There is also evidence that defective production of specific ribosomal proteins may stabilise p53 (Pestov et al., 2001; Sulic et al., 2005; Panic´et al., 2007; Fumagalli et al., 2009) . These studies were mainly based on models in which a derangement of ribosome biogenesis was developed more than a selective rRNA synthesis inhibition. Therefore, in these experimental models, the effect on p53 stabilisation may be ascribed only in part to the downregulation of rRNA transcription, but, in fact, was more likely related to ribosome biogenesis errors, decreased number of ribosomes, changes in the ratio of the 40S and 60S ribosome subunits, and defective ribosome translation (Panic´et al., 2007) . Indeed, specific disruption of 40S ribosome biogenesis upregulates the translation of mRNAs with a polypyrimidine tract at their 5 0 -transcriptional start site, including that encoding rpL11, which mediated p53 induction (Fumagalli et al., 2009) . However, there is no evidence that these ribosome perturbations may be induced by the environmental stresses that modulate p53 cell accumulation.
As for the observation of the lowering of p53 level and activity in conditions of rRNA synthesis upregulation, we are aware that the rRNA transcription was not exclusively and specifically induced in the three experimental models used. Therefore, the possibility that the reduced level of p53 might be the consequence of some mechanisms other than the stimulation of the rRNA synthesis cannot be ruled out as a matter of principle. However, the three models used, insulin/IGF-1 treatment, partial hepatectomy and cortisol stimulation are characterised by different pathways leading to an increased rRNA synthesis; nevertheless, all were associated with a downregulation of the p53 level and rRNA transcription modulates p53 G Donati et al activity. Furthermore, IGF-1 stimulation did not any longer reduce p53 stabilisation when the synthesis of rRNA was downregulated by POLR1A interference.
Our results, demonstrating that p53 stabilisation and activity were reduced in conditions of rRNA synthesis upregulation, might suggest also new ways for explaining why some pathological, non-tumour human tissue lesions are characterised by an increased risk of neoplastic transformation. Indeed, hormone-induced hyperplastic epithelial lesions and cell proliferative response to chronic inflammation represent important and frequent conditions that are associated with cancer development. As we found a close relationship between rRNA synthesis upregulation and the reduction of p53 function, we believe that a reduced tumour suppressor activity of p53 might contribute to increasing the risk of cancer development in the above mentioned tissue lesions, in which a stimulation of rRNA synthesis occurred as a consequence of the increased cell proliferation rate (Montanaro et al., 2008) . Furthermore, a reduced p53 activity consequent to rRNA synthesis upregulation might explain the increased risk of cancer onset in people with obesity, insulin resistance and type II diabetes, all conditions that are characterised by a hyperinsulinemic status with activation of the insulin and IGF-1 pathways (Renehan et al., 2006 (Renehan et al., , 2008 Frasca et al., 2008; Cannata et al., 2010) , and also might be responsible for the worse evolution of cancer in patients with the above mentioned metabolic features, by reducing the efficacy of the anti-tumour therapies that activate p53 (Renehan et al., 2006 (Renehan et al., , 2008 Frasca et al., 2008; Cannata et al., 2010) .
Materials and methods
Cell lines, culture conditions and drug treatments U2OS, HCT-116 and MCF7 human cancer-derived cell lines and H4-II-E-C3 rat hepatoma cell line were cultured in monolayer at 37 1C in humidified atmosphere containing 5% CO 2 in Dulbecco's modied Eagle's medium (Euroclone, Milan, Italy) supplemented with 10% foetal bovine serum (FBS, Euroclone), except MCF7 cells, which were grown in RPMI 1640 (Euroclone) plus 5% foetal bovine serum (Euroclone). Rat hepatocytes were isolated as previously described (Derenzini and Moyne, 1978) . Serum starvation was obtained by culturing cells in medium containing 0.2% foetal bovine serum. Actinomycin D (Biovision, Mountain View, CA, USA) was used at a final concentration of 8 nM; 5-fluorouracil (Teva Pharma Italia, Milan, Italy) was used at 75 mM; hydroxyurea (Sigma-Aldrich, Milan, Italy) was used at 3.4 mM; gemcitabine (Gemzar 200 mg; Eli Lilly Italia spa, Sesto Fiorentino, Italy) was used at the concentration of 10 mg/ml; rapamycin (Cell Figure 7 Schematic representation of how the balance between rRNA and ribosomal protein synthesis regulates p53 levels. (a) Homeostatic rRNA and ribosomal protein synthesis. The p53 level is controlled by the steady-state balance between rRNA and ribosomal protein synthesis. Ribosomal proteins not utilised for ribosome building bind to MDM2, thus regulating the MDM2-mediated p53 proteasomal degradation. (b) rRNA synthesis downregulation. After a downregulation of rRNA synthesis, the ribosomal proteins no longer engaged in ribosome biogenesis bind in larger amount to MDM2, thus reducing the MDM2-mediated p53 proteasomal degradation with the consequent increase of p53 stabilisation. (c) rRNA synthesis upregulation. After an upregulation of rRNA synthesis, a greater amount of ribosomal proteins are used for ribosome building, which are therefore no longer available for MDM2 binding. Thus, a greater portion of MDM2 is left free to induce p53 proteasomal degradation.
rRNA transcription modulates p53 G Donati et al Signaling Technology, Beverly, MA, USA) was used at 20 nM. a-Amanitin (Boehringer Mannheim, Mannheim, Germany) was dissolved in the culture medium at the concentration of 5 mg/ml. Human recombinant insulin-like growth factor (Sigma-Aldrich) was added to growth medium at a final concentration of 100 ng/ml; human recombinant insulin (NovoNordisk Farmaceutici, Rome, Italy) was used at 40 nM in growth medium; the proteasome inhibitor MG-132 (Calbiochem, Merck, Nottingham, UK) was used at a final concentration of 10 mM; Nutlin-3 (Sigma-Aldrich) was used at 5 mM; the ribosome inhibitor cycloheximide (Sigma-Aldrich) was used at a concentration of 20 mg/ml.
Animals
Four male Wistar rats (weighing 180-200 g) underwent partial (2/3) hepatectomy under anaesthesia, according to Higgins and Anderson (1931) , and 3 rats were intraperitoneally injected with cortisol (Sigma-Aldrich) at the dose of 10 mg/ 100 g body weight. Hepatectomised rats were killed 12 h after operation and 3 sham-operated rats were used as controls. Cortisol-treated rats were killed 8 h after drug injection and 3 rats injected with saline were used as controls. Experimental procedures were approved by the Ethical Committee of the University of Bologna.
RNAi, plasmids and transfection reagents Select stealth RNAi (Invitrogen, Carlsbad, UK) targeted against catalytic subunit of RNA Polymerase I (POLR1A) and siRNA against rpL11 (described by Barkic´et al. (2009) , target sequence 1) were used, whereas stealth RNAi negative control (Invitrogen) or a scrambled sequence siRNA was used to transfect controls, respectively. Cells were transfected with lipofectamine RNAiMAX (Invitrogen) in opti-MEM medium (Invitrogen), accordingly to manufacturer's procedures.
RNA extraction, reverse transcription and real-time PCR Cells were harvested and total RNA extracted with TRI reagent (Ambion, Austin, TX, USA), according to manufacturer instructions. Whole cell RNA was quantified spectrophotometrically and 2 mg of RNA for each sample were reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA), following the manufacturer's protocol. The relative amounts of POLR1A, 45S rRNA, rpL11, p21, Bax, PUMA, bglucuronidase, rat 45S rRNA, p21, Bax, PUMA, b-actin and 18S RNAs were evaluated by real-time PCR performed on an ABI Prism 7000 Sequence Detection System (Applied Biosystems) with the 2ÀDDCT method (Livak and Schmittgen, 2001) . The mean DCT value of the control sample was used in each experiment to calculate the DDCT value of sample replicates. POLR1A, p21 and the internal control b-glucuronidase mRNAs were quantified with TaQMan Gene Expression Assays primers and probe kits (Applied Biosystems); primers and UPL probe (Roche Diagnostics, Milan, Italy) for rpL11 and rpL5 were chosen with the Roche online primer design tool, primers for SYBR Green real-time PCR analysis of human Bax, PUMA and rat p21, Bax, and PUMA were designed using the same online tool; primers for human and rat 45S rRNA have been already described by Grandori et al. (2005) and Murayama et al. (2008) , respectively. All sequences are available upon request.
Isolation of polyribosomal mRNA Subconfluent cells were washed in phosphate-buffered saline (PBS) at 4 1C. The cellular pellet was lysed in two volumes of 10 mmol/l Tris-HCl (pH 7.4), 10 mmol/l NaCl, 3 mmol/l MgCl 2 and 0.5% NP40 for 10 min at 4 1C. The lysates were then centrifuged at 14 000 g for 10 min at 4 1C and the supernatant was used for the isolation of polyribosomes. Lysates were stratified onto a 15-50% sucrose gradient in 30 mmol/l HEPES/KOH (pH 7.5), 80 mmol/l KCl, 1.8 mmol/l Mgacetate, and centrifuged at 4 1C for 15 h at 40 000 g. From gradients, 1-ml fractions were collected and their absorbance was read at 260 nm. Polyribosomal fractions were pooled and centrifuged at 100 000 g for 15 h at 4 1C. RNA was extracted from pellets using Trizol reagent.
Electron microscopy Cells were immediately fixed in a solution of 4% formaldehyde in 0.1 M So¨rensen buffer, pH 7.2 and postfixed in 1% osmium tetroxide in the same buffer. All the samples were dehydrated in alcohol and embedded in Epon. Ultrathin sections were double stained with uranyl acetate and lead citrate.
Immunofluorescence Cells grown on glass coverslips were fixed and permeabilised in PBS containing 2% paraformaldehyde and 1% Triton X-100 for 5 min at room temperature.
Samples were incubated for 30 min in PBS plus 1% bovine serum albumin (Sigma-Aldrich) to block nonspecific binding before incubating with the primary antibody diluted in PBS plus 1% bovine serum albumin overnight at 4 1C. The samples were rinsed in PBS and then incubated with fluorescein isothiocyanate (FITC)-conjugated anti-mouse secondary antibody (Dako, Glostrup, Denmark) for 45 min at 37 1C in the dark in a humidified chamber. Mounting and nuclei counterstaining were performed using the 'pro long antifade reagent with DAPI' (Molecular Probes, Invitrogen) and observed under a fluorescence microscope (Carl Zeiss Italy, Milano, Italia).
Analysis of rRNA synthesis by 5-fluorouridine incorporation Analysis of nascent rRNA was performed on cells grown on coverslips by incorporation of 5-fluorouridine accordingly to the method described by Boisvert et al. (2000) . Briefly, cells were incubated for 15 min in medium containing 2 mM 5-fluorouridine (Sigma-Aldrich), then washed in cold PBS and fixed in 2% paraformaldehyde and 1% Triton X-100 for subsequent immunofluorescence, performed as described above, using a monoclonal antibody specific for 5-fluorouridine.
Western blotting
Whole cell protein extracts and subsequent SDS-polyacrylamide gel electrophoresis and immunoblot analyses were made as already described (Montanaro et al., 2007) . Briefly, total cellular proteins were extracted in lysis buffer (KH 2 PO 4 0.1 M pH 7.5, NP-40 1%, added with Complete protease inhibitors cocktail (Roche Diagnostics) and 0.1 mM b-glycerolphosphate) and quantified spectrophotometrically with the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hempstead, UK).
Nuclear proteins fraction for western blot analysis was obtained accordingly to the method described by Abmayr et al. (2006) , with slight modifications. Proteins immobilized on nitrocellulose membranes (GE-Healthcare Italia, Milano, Italy) were blotted overnight at 4 1C with primary antibody. Horseradish peroxidase-conjugated secondary antibody were from Santa Cruz Biotechnology (CA, USA) and GE-Healthcare (anti-mouse).
Immunoprecipitation
Cells were lysed in buffer containing 50 mM Tris/HCl (pH 8.0), 150 mM NaCl, 0.8% NP40, 1 mM dithiothreitol, 1 mM EDTA and Complete protease inhibitors cocktail (Roche Diagnostics). For each sample, 2.0 mg of proteins were pre-cleared with Protein A/G PLUS-Agarose beads (Santa Cruz Biotechnology) at 4 1C for 30 min and subsequently incubated for 6 h at 4 1C with anti-MDM2 polyclonal antibodies. The immunocomplexes were then precipitated with Protein A/G PLUSAgarose beads for 2 h at 4 1C. The beads were then centrifuged, washed four times in lysis buffer and resuspended in Laemmli buffer for subsequent immunoblot analysis.
